The Food and Drug Administration (FDA) warns that the popular smoking cessation drug Chantix may increase patients' risk of chest pain and heart attack.
Chantix was approved in May 2006 and has been used by millions of Americans to help them stop smoking. Sales have declined, however, since 2008 – when the prescription medication was linked to risk of suicidal thoughts and depression. The drug's current label warns users about these side effects.
A new study of 700 patients showed that those taking Chantix experienced more heart problems – including heart attack and chest pain – than those taking a placebo drug. The FDA will add new warnings about the risk of heart problems to the drug's label. Patients will also receive new medication guides outlining those risks.
The drug's manufacturer, Pfizer, will be required to analyze a larger group of studies to determine how much Chantix patients are at risk. Another smoking cessation drug, Zyban, carries the same warning about heart-related side effects.
For more information about Chantix, visit EdgarSnyder.com.